Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG4 multivalent pneumococcal vaccine in healthy toddlers
NCT06531538Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of PG4 in pneumococcal disease (3 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting prespecified local reactions, Percentage of participants reporting prespecified systemic events and 2 more. Started Jul 2024; status: completed.
02
Drugs
PG4
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06531538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531538.